×

Foamix to Present Corporate Overview at the Jefferies 2015 Global Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, N.J., May 28, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, Chief Executive Officer, will provide a corporate overview and business update at the Jefferies 2015 Global Healthcare Conference.

Presentation Details:
Title: Jefferies 2015 Global Healthcare Conference
Date: Thursday, June 4
Time: 9:00am Eastern Time
Location: Grand Hyatt Hotel, New York City
Webcast: http://wsw.com/webcast/jeff88/fomx

About Foamix Pharmaceuticals

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals' lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.

CONTACT: Dorit Hayon, BD manager Foamix Pharmaceuticals Ltd. +972-8-9316233 ir@foamixpharma.com U.S. Investor Relations Andrew McDonald LifeSci Advisors, LLC 646-597-6987 andrew@lifesciadvisors.com

Source:Foamix, Ltd.